Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension

American Journal of Hypertension

Volumn 11, Issue 6 I, 1998, Pages 690-696

  Östergren, Jan ^a   Isaksson, Hans ^b   Brodin, Ulf ^c   Schwan, Åke ^d   Öhman, K Peter ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ambulatory blood pressure; Amlodipine; Circadian variation; Felodipine; Plasma half life

Indexed keywords

AMLODIPINE; FELODIPINE;

AMBULATORY MONITORING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

EID: 0031864054     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00032-6     Document Type: Article

References (19)

1. Millar-Craig M.W., Bishop C.N., Raftery E.B. Circadian variation of blood pressure. Lancet. i:1978;795-797.
2. Pickering T.G. Ambulatory Monitoring and Blood Pressure Variability. 1991;Science Press, London.
3. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 313:1985;1315-1322.
4. Muller J.E., Ludmer P.L., Willich S.N., et al. Circadian variation in the frequency of onset of sudden cardiac death. Circulation. 75:1987;131-138.
5. Leenen F.H.H. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. Am J Hypertens. 9:(suppl):1996;97S-104S.
6. Meredith P.A., Elliot H.L. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinetics. 22:1992;22-31.
7. Edgar B., Collste P., Haglund K., et al. Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. Clin Invest Med. 10:1987;388-394.
8. Fariello R., Boni E., Corda L., et al. Extended release felodipine in essential hypertension. Am J Hypertens. 4:1991;17-33.
9. Kelley J.G., O'Malley K. Clinical pharmacokinetics of calcium antagonists an update . Clin Pharmacokinet. 22:1992;416-443.
10. Kleinbloessem C.H., van Brummelen P., Danhof M., et al. Rate-of-increase of plasma concentrations of nifedipine as a major determinant of its haemodynamic effect in humans. Clin Pharmacol Ther. 41:1987;26-30.
11. Blychert E., Hedner T., Dahlöf C., Elmfeldt D. Plasma concentration effect relationships of intravenous and extended release oral felodipine in hypertensive patients. J Cardiovasc Pharmacol. 15:1990;428-435.
12. Donelly R., Meredith P.A., Miller S.H.K., et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther. 54:1993;303-310.
13. Myers M.G., Leenen F.H.H., Tanner J. Differential effects of felodipine and nifedipine on 24 hour blood pressure and left ventricular mass. Am J Hypertens. 8:1995;712-718.
14. Bainbridge A.D., Herlihy O., Meredith P.A., Elliot H.L. A comparative assessment of amlodipine and felodipine ER pharmacokinetic and pharmacodynamic indices . Eur J Clin Pharmacol. 45:1993;425-430.
15. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke and coronary heart disease. Lancet. 335:1990;765-774.
16. Heber M.E., Brigden G., Al-Khawaja, Raftery E.B. 24 h blood pressure control with the once daily calcium antagonist, amlodipine. Br J Clin Pharmacol. 27:1989;359-365.
17. Julius S. Amlodipine in hypertension an overview of the clinical dossier . J Cardiovasc Pharmacol. 12:1988;S27-S33.
18. van der Krogt J., Brand R., Dawson E.C. Amlodipine versus extended release felodipine in general practice a randomized, parallel-group study in patients with mild-to-moderate hypertension . Curr Therapeutic Res. 57:1996;145-158.
19. Hoegholm A., Wiinberg N., Rasmussen E., et al. Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. J Human Hypertens. 9:(suppl 1):1995;S25-S28.